Albany Molecular Research News

Forward-Looking Statements The following discussion of our results of operations and financial condition should be read in conjunction with the accompanying Condensed Consolidated Financial Statements and the Notes thereto included within this report.

As a leading provider of free in depth reports and timely market updates, Paragon is an essential resource for hundreds of thousands of investors across the country.

Good day, ladies and gentlemen and welcome to the AMRI First Quarter Earnings Release Conference Call.

Albany, NY AMRI today reported financial and operating results for the first quarter ended March 31, 2013.

Albany Molecular Research issued its quarterly earnings data on Tuesday. The company reported $0.23 earnings per share for the quarter, StocKRatingsNetwork.com reports.

AMRI co-founder and chief Thomas D'Ambra earned a $300,000 bonus in 2012. He declined it, asking that it go to charity and other AMRI employees.

Going into 2012, some analysts wondered about the future of CRO/CMO Albany Molecular Research, Inc.

Tired of waiting for resolution with preservationists, planners at the Buffalo Niagara Medical Campus are looking at building a second Innovation Center on the site of a city-owned parking ramp at Goodrich and Ellicott.

Thomas D'Ambra, CEO of AMRI, earned $3.78 million in 2012. That included $3.18 million in royalty payments from sales of Allegra.

Albany Molecular Research, Inc. is a global contract research and manufacturing organization offering customers fully integrated drug discovery, development and manufacturing services.